Skip to Content

Questran Light (cholestyramine) and Alcohol / Food Interactions

There is 1 alcohol/food/lifestyle interaction with Questran Light (cholestyramine):


cholestyramine ↔ multivitamins with minerals

Moderate Drug Interaction

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Bile acid sequestrants and the phosphate binder, sevelamer, can decrease the absorption of fat-soluble vitamins A, D, E, and K. In non-clinical safety studies, rats administered colesevelam at doses greater than 30-fold the projected human clinical dose developed hemorrhage in association with vitamin K deficiency. In a crossover study involving healthy subjects, coadministration of sevelamer with calcitriol resulted in a significant reduction in bioavailability for calcitriol (calcitriol with sevelamer vs calcitriol alone: AUC 137 pg*h/mL vs 318 pg*h/mL and Cmax 40.1 pg/mL vs 49.7 pg/mL, respectively).

MANAGEMENT: Oral vitamin supplements should be administered at least 4 hours before colesevelam and either 1 hour before or 4 to 6 hours after other bile acid sequestrants and sevelamer.


  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Peirce D, Hossack S, Poole L, "The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol." Nephrol Dial Transplant 26 (2011): 1615-21
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Rocaltrol (calcitriol)." Roche Laboratories, Nutley, NJ.
  5. "Product Information. Welchol (colesevelam)" Daiichi Sankyo, Inc., Parsippany, NJ.
View all 5 references

Questran Light (cholestyramine) drug interactions

There are 322 drug interactions with Questran Light (cholestyramine)

Questran Light (cholestyramine) disease interactions

There are 5 disease interactions with Questran Light (cholestyramine) which include:

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.